CUE - Cue Biopharma, Inc.
Previous close
1.09
0.010 0.917%
Share volume: 1,709
Last Updated: Fri 27 Dec 2024 08:25:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.08
0.01
0.93%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-14 | 2023-03-21 | 2023-05-09 | 2023-08-08 | 2023-11-03 | 2024-03-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 84.749 M | 76.300 M | 91.283 M | 81.682 M | 73.163 M | 68.888 M | 61.530 M | 53.951 M | |
| Current Assets | 69.004 M | 61.700 M | 77.187 M | 68.755 M | 60.935 M | 57.517 M | 51.454 M | 44.669 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.142 M | 1.721 M | 841.217 K | 2.360 M | 1.911 M | 1.165 M | 1.242 M | 2.240 M | |
| Short Term Investments | 2.142 M | 1.721 M | 841.217 K | 2.360 M | 1.911 M | 1.165 M | 1.242 M | 2.240 M | |
| Total Receivables | 736.000 K | 796.000 K | 57.252 K | 196.000 K | 1.135 M | 1.661 M | 1.698 M | 1.400 M | |
| Current Cash | 66.126 M | 59.183 M | 76.289 M | 66.199 M | 57.889 M | 54.691 M | 48.514 M | 41.029 M | |
| Total Non-current Assets | 15.745 M | 14.600 M | 14.096 M | 12.927 M | 12.228 M | 11.371 M | 10.076 M | 9.282 M | |
| Property Plant Equipment | 1.765 M | 1.642 M | 1.499 M | 1.325 M | 1.192 M | 1.064 M | 795.000 K | 754.000 K | |
| Other Assets | 13.830 M | 12.808 M | 12.447 M | 11.602 M | 10.886 M | 10.157 M | 9.130 M | 8.377 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 84.749 M | 76.300 M | 91.283 M | 81.682 M | 73.163 M | 68.888 M | 61.530 M | 53.951 M | |
| Total liabilities | 24.993 M | 25.536 M | 25.601 M | 26.665 M | 27.159 M | 26.222 M | 24.445 M | 23.913 M | |
| Total current liabilities | 8.323 M | 10.222 M | 11.549 M | 13.810 M | 16.307 M | 17.207 M | 17.081 M | 18.090 M | |
| Accounts Payable | 1.568 M | 2.045 M | 2.731 M | 2.151 M | 2.356 M | 2.480 M | 3.501 M | 3.919 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 445.000 K | 136.000 K | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 3.196 M | 4.298 M | 5.263 M | 6.295 M | 7.328 M | 7.362 M | 7.331 M | 7.173 M | |
| Long term debt | 16.670 M | 15.314 M | 14.052 M | 12.410 M | 10.716 M | 9.015 M | 7.364 M | 5.823 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 445.000 K | 136.000 K | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 59.756 M | 50.764 M | 65.683 M | 55.017 M | 46.004 M | 42.666 M | 37.085 M | 30.038 M | |
| Common stock | 35.357 M | 35.383 M | 39.219 M | 44.652 M | 44.799 M | 46.359 M | 47.210 M | 49.467 M | |
| Retained earnings | -224.909 M | -235.864 M | -250.457 M | -263.565 M | -276.750 M | -287.755 M | -301.190 M | -313.537 M |